Fatigue News and Research

RSS

Eisai receives FDA approval for Fycompa to treat partial onset seizures

The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.

23 Oct 2012

Simple 10-minute Tension Tamer could help relieve stress and decrease fatigue

A simple, 10-minute stress reduction technique could help to relieve stress, improve sleep quality, and decrease fatigue.

22 Oct 2012

Brain Injury Research Center of Mount Sinai receives fund to research on TBI

The Brain Injury Research Center of Mount Sinai has received two prestigious grants totaling $6.65 million to fund research on traumatic brain injury over the next five years.

20 Oct 2012

Integrative Medicine helps people heal faster

The body has an innate desire to heal itself. Encouraging self-healing is the focus of Greenwich Hospital's Integrative Medicine Program.

19 Oct 2012

Tool reveals myeloproliferative neoplasm patient burden

Researchers have devised a tool to accurately assess the extent of symptoms in patients with myeloproliferative neoplasms.

17 Oct 2012

Major academic medical centers, teaching hospitals to form Chicago Adult Congenital Heart Network

Seven major academic medical centers and teaching hospitals in the Chicago area have joined together to form the Chicago Adult Congenital Heart Network (CATCH), which is the first patient-centered, inter-institutional network in Chicago established to ensure all adults with congenital heart disease in the area receive appropriate follow-up care.

16 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Safety tips to avoid common farm injuries

The hectic fall harvest is under way, and that means the dangers of everyday farm work -- one of the nation's most hazardous occupations -- are compounded by the rush to bring in crops on time. Many agricultural injuries can be prevented with basic safety equipment and mindfulness about the need for caution on the job, says emergency medicine physician Howard Schumaker, M.D., of the Mayo Clinic Health System in Sparta.

11 Oct 2012

Migraine therapy alleviates more than just the headache

Treating the pain associated with migraine can also improve the social and psychologic problems experienced by individuals affected by the condition, findings from a systematic review suggest.

10 Oct 2012

FMCNA urges dialysis patients to get flu shots

With flu season just around the corner, Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is urging dialysis patients to get flu shots to protect themselves against this common infectious disease. In October, FMCNA will begin offering at no cost to all of its dialysis patients and staff, flu vaccinations, which protect against both seasonal flu and H1N1 swine flu.

6 Oct 2012

Tips to differentiate between children's cold and allergies

One of the problems that parents may have during the fall is deciphering whether their children's sneezing is due to a cold or allergies.

6 Oct 2012

Many breast cancer survivors insufficiently active after leaving supervised programs

More than 40 percent of older breast cancer survivors are insufficiently active after leaving a supervised program. But new research shows that those women who developed behavioral skills such as self-confidence and motivation during their program were far more likely to continue exercising on their own.

6 Oct 2012

Beta-blockers not associated with reduced risk of heart attacks, death and strokes

A new study conducted by researchers in the Cardiac and Vascular Institute at NYU Langone Medical Center, found using beta-blockers, the standard of care for patients with coronary artery disease (CAD), was not associated with a lower risk of heart attacks, death and strokes in patients suffering from CAD and those with risk factors for the disease, including those with a history of heart attack.

4 Oct 2012

Alarms could be key to avoiding intraoperative awareness

Bispectral index monitoring is unlikely to be better than monitoring based on anesthetic concentrations for preventing intraoperative awareness, shows a randomized trial.

3 Oct 2012

Improvements to diagnosis and screening of sleep apnea are critical to stroke prevention

Improvements to the diagnosis and screening of sleep apnea are critical to stroke prevention, according to new stroke care guidelines released today at the Canadian Stroke Congress.

3 Oct 2012

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

3 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012